Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities

Kras-driven non-small-cell lung cancers (NSCLCs) are a leading cause of death with limited therapeutic options. Many NSCLCs exhibit high levels of Ezh2, the enzymatic subunit of polycomb repressive complex 2 (PRC2). We tested Ezh2 inhibitors as single agents or before chemotherapy in mice with ortho...

Full description

Bibliographic Details

Published in:	The Journal of experimental medicine Vol. 215; no. 12; p. 3115
Main Authors:	Serresi, Michela, Siteur, Bjorn, Hulsman, Danielle, Company, Carlos, Schmitt, Matthias J, Lieftink, Cor, Morris, Ben, Cesaroni, Matteo, Proost, Natalie, Beijersbergen, Roderick L, van Lohuizen, Maarten, Gargiulo, Gaetano
Format:	Journal Article
Language:	English
Published:	United States 03.12.2018
ISSN:	1540-9538, 1540-9538
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!